Vis enkel innførsel

dc.contributor.authorVoshaar, Marieke
dc.contributor.authorVriezekolk, Johanna
dc.contributor.authorvan Dulmen, Sandra
dc.contributor.authorvan den Bemt, Bart
dc.contributor.authorVan De Laar, Mart
dc.date.accessioned2018-02-23T09:41:17Z
dc.date.available2018-02-23T09:41:17Z
dc.date.created2016-12-28T12:09:11Z
dc.date.issued2016
dc.identifier.citationBMC Musculoskeletal Disorders. 2016, 17 .nb_NO
dc.identifier.issn1471-2474
dc.identifier.urihttp://hdl.handle.net/11250/2486661
dc.description.abstractBackground: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatment for inflammatory rheumatic diseases, medication adherence to DMARDs is often suboptimal. Effective interventions to improve adherence to DMARDs are lacking, and new targets are needed to improve adherence. The aim of the present study was to explore patients’ barriers and facilitators of optimal DMARD use. These factors might be used as targets for adherence interventions. Methods: In a mixed method study design, patients (n = 120) with inflammatory arthritis (IA) completed a questionnaire based on an existing adapted Theoretical Domains Framework (TDF) to identify facilitators and barriers of DMARD use. A subgroup of these patients (n = 21) participated in focus groups to provide insights into their facilitators and barriers. The answers to the questionnaires and responses of the focus groups were thematically coded by three researchers independently and subsequently categorized. Results: The barriers and facilitators that were reported by IA patients presented large inter-individual variations. The identified barriers and facilitators could be captured in the following domains based on an adapted TDF: (i) knowledge, (ii) emotions, (iii) attention, memory, and decision processes, (iv) social influences, (v) beliefs about capability, (vi) beliefs about consequences, (vii) motivation and goals, (viii) goal conflict, (ix) environmental context and resources, and (x) skills. Conclusions: Patients with IA have a variety of barriers and facilitators with regard to their DMARD use. All of these barriers and facilitators could be categorized into adapted domains of the TDF. Interventions that address individual facilitators and barriers, based on capability, opportunity, and motivation, are needed to develop strategies for medication adherence that are tailored to individual patient needs.nb_NO
dc.language.isoengnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleBarriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: A qualitative theory-based studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.rights.holderThe Authorsnb_NO
dc.source.volume17nb_NO
dc.source.journalBMC Musculoskeletal Disordersnb_NO
dc.identifier.doi10.1186/s12891-016-1289-z
dc.identifier.cristin1417713
cristin.unitcode222,56,1,0
cristin.unitnameInstitutt for sykepleie- og helsevitenskap
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal